Example of Expert Opinion on Drug Safety format
Recent searches

Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format Example of Expert Opinion on Drug Safety format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Expert Opinion on Drug Safety — Template for authors

Publisher: Taylor and Francis
Categories Rank Trend in last 3 yrs
Pharmacology (medical) #46 of 246 down down by 12 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 505 Published Papers | 3105 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 19/07/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 6.4
SJR: 1.187
SNIP: 1.192
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.1
SJR: 1.333
SNIP: 1.061
open access Open Access

SAGE

Quality:  
High
CiteRatio: 4.8
SJR: 1.164
SNIP: 1.22
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.3
SJR: 1.196
SNIP: 1.603

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

3.383

5% from 2018

Impact factor for Expert Opinion on Drug Safety from 2016 - 2019
Year Value
2019 3.383
2018 3.22
2017 3.156
2016 3.439
graph view Graph view
table view Table view

6.1

2% from 2019

CiteRatio for Expert Opinion on Drug Safety from 2016 - 2020
Year Value
2020 6.1
2019 6.2
2018 6.3
2017 6.3
2016 5.1
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has increased by 5% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has decreased by 2% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.086

11% from 2019

SJR for Expert Opinion on Drug Safety from 2016 - 2020
Year Value
2020 1.086
2019 0.975
2018 1.007
2017 1.112
2016 1.297
graph view Graph view
table view Table view

1.282

12% from 2019

SNIP for Expert Opinion on Drug Safety from 2016 - 2020
Year Value
2020 1.282
2019 1.142
2018 1.025
2017 1.087
2016 1.016
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has increased by 11% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 12% in last years.
  • This journal’s SNIP is in the top 10 percentile category.
Expert Opinion on Drug Safety

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Taylor and Francis

Expert Opinion on Drug Safety

Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, ...... Read More

Medicine

i
Last updated on
18 Jul 2020
i
ISSN
1474-0338
i
Impact Factor
High - 1.097
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Green faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
Taylor and Francis Custom Citation
i
Citation Type
Numbered
[25]
i
Bibliography Example
Blonder GE, Tinkham M, Klapwijk TM. Transition from metallic to tunneling regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys Rev B. 1982; 25(7):4515–4532. Available from: 10.1103/PhysRevB.25.4515.

Top papers written in this journal

open accessOpen access Journal Article DOI: 10.1517/14740338.2013.827660
Clinical consequences of polypharmacy in elderly
Robert L. Maher1, Joseph T. Hanlon2, Emily R. Hajjar3

Abstract:

Introduction: Polypharmacy, defined as the use of multiple drugs or more than are medically necessary, is a growing concern for older adults. MEDLINE and EMBASE databases were searched from January 1, 1986 to June 30, 2013) to identify relevant articles in people aged > 65 years. Areas covered: We present information about: i... Introduction: Polypharmacy, defined as the use of multiple drugs or more than are medically necessary, is a growing concern for older adults. MEDLINE and EMBASE databases were searched from January 1, 1986 to June 30, 2013) to identify relevant articles in people aged > 65 years. Areas covered: We present information about: i) prevalence of polypharmacy and unnecessary medication use; ii) negative consequences of polypharmacy; and iii) interventions to improve polypharmacy. Expert opinion: International research shows that polypharmacy is common in older adults with the highest number of drugs taken by those residing in nursing homes. Nearly 50% of older adults take one or more medications that are not medically necessary. Research has clearly established a strong relationship between polypharmacy and negative clinical consequences. Moreover, well-designed interprofessional (often including clinical pharmacist) intervention studies that focus on enrolling high-risk older patients with polypharmacy have sh... read more read less

Topics:

Polypharmacy (73%)73% related to the paper, Deprescriptions (60%)60% related to the paper
View PDF
1,279 Citations
Journal Article DOI: 10.1517/14740338.2016.1140743
Long-term side effects of glucocorticoids
Merih Oray1, Khawla Abu Samra, Nazanin Ebrahimiadib, Halea Meese, C. Stephen Foster2

Abstract:

Introduction: Glucocorticoids represent the standard therapy for reducing inflammation and immune activation in various diseases. However, as with any potent medication, they are not without side effects. Glucocorticoid-associated side effects may involve most major organ systems. Musculoskeletal, gastrointestinal, cardiovasc... Introduction: Glucocorticoids represent the standard therapy for reducing inflammation and immune activation in various diseases. However, as with any potent medication, they are not without side effects. Glucocorticoid-associated side effects may involve most major organ systems. Musculoskeletal, gastrointestinal, cardiovascular, endocrine, neuropsychiatric, dermatologic, ocular, and immunologic side effects are all possible.Areas Covered: This article analyzes English-language literature and provides an update on the most recent literature regarding side effects of systemic glucocorticoid treatment.Expert Opinion: The risk/benefit ratio of glucocorticoid therapy can be improved by proper use. Careful monitoring and using appropriate preventive strategies can potentially minimize side effects. read more read less

Topics:

Glucocorticoid (51%)51% related to the paper
404 Citations
Journal Article DOI: 10.1517/14740338.6.5.609
Paclitaxel: a review of adverse toxicities and novel delivery strategies.
Neena I. Marupudi1, James E. Han1, Khan W. Li1, Violette M Renard1, Betty Tyler, Henry Brem

Abstract:

Better known as Taxol (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The use of paclitaxel as a chemotherapeutic agent has become a b... Better known as Taxol (Bristol-Myers Squibb), paclitaxel is the first member of the taxane family to be used in cancer chemotherapy. The taxanes exert their cytotoxic effect by arresting mitosis through microtubule stabilization, resulting in cellular apoptosis. The use of paclitaxel as a chemotherapeutic agent has become a broadly accepted option in the treatment of patients with ovarian, breast and non-small cell lung cancers, malignant brain tumors, and a variety of other solid tumors. However, significant toxicities, such as myelosuppression and peripheral neuropathy, limit the effectiveness of paclitaxel-based treatment regimens. This review addresses the toxicities associated with paclitaxel treatment and describes existing and future strategies of paclitaxel administration directed at limiting these toxicities. read more read less

Topics:

Paclitaxel (59%)59% related to the paper, Taxane (58%)58% related to the paper
356 Citations
Journal Article DOI: 10.1517/14740338.2014.950653
Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis

Abstract:

Introduction: Recent reports have significantly halted the enthusiasm regarding androgen-boosting; suggesting that testosterone supplementation (TS) increases cardiovascular (CV) events.Areas covered: In order to overcome some of the limitations of the current evidence, the authors performed an updated systematic review and m... Introduction: Recent reports have significantly halted the enthusiasm regarding androgen-boosting; suggesting that testosterone supplementation (TS) increases cardiovascular (CV) events.Areas covered: In order to overcome some of the limitations of the current evidence, the authors performed an updated systematic review and meta-analysis of all placebo-controlled randomized clinical trials (RCTs) on the effect of TS on CV-related problems. Out of 2747 retrieved articles, 75 were analyzed, including 3016 and 2448 patients in TS and placebo groups, respectively, and a mean duration of 34 weeks. Our analyses, performed on the largest number of studies collected so far, indicate that TS is not related to any increase in CV risk, even when composite or single adverse events were considered. In RCTs performed in subjects with metabolic derangements a protective effect of TS on CV risk was observed.Expert opinion: The present systematic review and meta-analysis does not support a causal role between TS and adver... read more read less

Topics:

Meta-analysis (51%)51% related to the paper, Randomized controlled trial (51%)51% related to the paper
264 Citations
open accessOpen access Journal Article DOI: 10.1080/14740338.2018.1546841
An update on the clinical consequences of polypharmacy in older adults: a narrative review
Jonas W. Wastesson1, Lucas Morin1, Edwin C.K. Tan1, Kristina Johnell1

Abstract:

Introduction: Polypharmacy, the use of multiple medications by one individual, is increasingly common among older adults. Caring for the growing number of older people with complex drug regimens an ... Introduction: Polypharmacy, the use of multiple medications by one individual, is increasingly common among older adults. Caring for the growing number of older people with complex drug regimens an ... read more read less

Topics:

Polypharmacy (69%)69% related to the paper, Drug Utilization (51%)51% related to the paper
View PDF
263 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Expert Opinion on Drug Safety.

It automatically formats your research paper to Taylor and Francis formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Expert Opinion on Drug Safety format uses Taylor and Francis Custom Citation citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Expert Opinion on Drug Safety in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Expert Opinion on Drug Safety guidelines and auto format it.

2. Do you follow the Expert Opinion on Drug Safety guidelines?

Yes, the template is compliant with the Expert Opinion on Drug Safety guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Expert Opinion on Drug Safety?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Expert Opinion on Drug Safety citation style.

4. Can I use the Expert Opinion on Drug Safety templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Expert Opinion on Drug Safety.

5. Can I use a manuscript in Expert Opinion on Drug Safety that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Expert Opinion on Drug Safety that you can download at the end.

6. How long does it usually take you to format my papers in Expert Opinion on Drug Safety?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Expert Opinion on Drug Safety.

7. Where can I find the template for the Expert Opinion on Drug Safety?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Expert Opinion on Drug Safety's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Expert Opinion on Drug Safety's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Expert Opinion on Drug Safety an online tool or is there a desktop version?

SciSpace's Expert Opinion on Drug Safety is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Expert Opinion on Drug Safety?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Expert Opinion on Drug Safety?”

11. What is the output that I would get after using Expert Opinion on Drug Safety?

After writing your paper autoformatting in Expert Opinion on Drug Safety, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Expert Opinion on Drug Safety's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Expert Opinion on Drug Safety?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Expert Opinion on Drug Safety. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Expert Opinion on Drug Safety?

The 5 most common citation types in order of usage for Expert Opinion on Drug Safety are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Expert Opinion on Drug Safety?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Expert Opinion on Drug Safety's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Expert Opinion on Drug Safety in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Expert Opinion on Drug Safety Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Expert Opinion on Drug Safety formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template